European Geriatric Medicine, 10(1) Palmer, K, Villani, E R, Vetrano, D L, Cherubini, A, Cruz-Jentoft, A J, Curtin, D, Denkinger, M, Gutiérrez-Valencia, M, Guðmundsson, A, Knol, W, Mak, D V, O’Mahony, D, Pazan, F, Petrovic, M, Rajkumar, C, Topinkova, E, Trevisan, C, van der Cammen, T J M, van Marum, R J, Wehling, M, Ziere, G, Bernabei, R, Onder, G & On behalf of the European Geriatric Medicine Society Pharmacology special interest group 2019, ' Association of polypharmacy and hyperpolypharmacy with frailty states: a systematic review and meta-analysis ', European Geriatric Medicine, vol. 10, no. 1, pp. 9-36 . https://doi.org/10.1007/s41999-018-0124-5 European Geriatric Medicine, 10(1), 9-36. Elsevier Masson European Geriatric Medicine, 10(1), 9. Elsevier Masson
Diabetes, obesity and metabolism 21 (2019): 1177–1190. doi:10.1111/dom.13639 info:cnr-pdr/source/autori:Piero Ruggenenti; Matias Trillini; Drazenka P. Barlovic; Monica Cortinovis; Antonio Pisani; Aneliya Parvanova; Ilian Iliev; Barbara Ruggiero; Stefano Rota; Maria C Aparicio; Annalisa Perna; Francesco Peraro; Olimpia Diadei; Flavio Gaspari; Fabiola Carrara; Nadia Stucchi; Davide Martinetti; Andrej Janez; Nadah Gregoric; Eleonora Riccio; Antonio C. Bossi; Roberto Trevisan; Paolo Manunta; Giovanni Battaglia; Salvatore David; Filippo Aucella; Antonio Belviso,; Andrea Satta; Giuseppe Remuzzi/titolo:Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial/doi:10.1111%2Fdom.13639/rivista:Diabetes, obesity and metabolism (Print)/anno:2019/pagina_da:1177/pagina_a:1190/intervallo_pagine:1177–1190/volume:21